Thyroid hormones and heart mitochondrial nitric oxide under hypovolemia

Abstract

The aim of the present work was to examine the effect of thyroid state on rat heart mitochondria function during hypovolemia. Sprague-Dawley rats treated with T3 (hyper, 20 µg/100 g body weight) or 0.02% methimazole (hypo, w/v) for 28 days. Hypovolemia was induced by acute hemorrhage. O2 uptake, complex I activity and mitochondrial nitric oxide synthase (mtNOS) protein levels were determined in heart mitochondria. The malate-glutamate-supported state 3 respiration decreased and increased in hypo and hyperthyroid rats, while state 4 respirations did not change. Complex I activity and mtNOS protein levels were decreased in hypothyroid rats even in acute hypovolemia. Hyperthyroidism did not change these parameters. In summary, this study showed, for the first time, interesting findings that heart mitochondrial function is altered during thyroid disorder and acute hypovolemia. Heart mitochondrial nitric oxide, modulating oxygen uptake, may be involved in the adaptive response to assure the cardiomyocytes survives in this experimental condition.

Keywords: thyroid gland, cardiomyocytes, oxygen uptake, mtNOS, complex I

Introduction

The thyroid hormones are known as one of the major factors that regulate cardiac metabolic and physiological functions. Mitochondria is considered a subcellular target of thyroid hormone action and a major compartment of this hormone accumulation. In recent years, nitric oxide (NO) signaling has been identified as an important trigger of cardioprotection in the mitochondria. It is synthesized from L-arginine, NADPH and O2 in a reaction catalyzed by mitochondria NO synthase (mtNOS) isoform located in the mitochondrial inner membrane. The mtNOS is the α splice variant of neuronal nitric oxide synthetase isoform resulting in a novel Ca2+ dependent NOS subtyped. Thyroid hormones modulate NO steady-state level which may act as a messenger to modulate the mitochondrial bioenergetic function.

Materials and methods

Animals

Male Sprague-Dawley rats of 2 months old from the breeding laboratories of the School of Pharmacy and Biochemistry (Universidad de Buenos Aires, Argentina) were used throughout the study. Rats were housed in humidity- and temperature-controlled environment with an automatic 12h light: 12h darkness cycle. All procedures were reviewed and approved by the National Food, Drug and Medical Technology Administration (ANMAT), National Department of Health and Environment, Argentina (No. 6344/96) and CICUAL No 0054570. Rats were randomly assigned to one of the three groups:

Control rats (Eut, n=16), animals who received i.p injections of 0.9% NaCl (0.1 ml/100g body weight) every 2nd day for 28 days.

T3-treated rats (Hyper, n=16), animals received i.p injections of triiodothyronine (T3) (Sigma, 20 ug/100g body weight) every 2nd day for 28 days.

Methimazole-treated rats (hypo, n=16), animals were rendered hypothyroid after 28 days of treatment with 0.02% methimazole (w/v) in the drinking water.

Determination of treatment efficacy

Serum thyroid-stimulating hormone (TSH), total T3 and thyroxin (T4) (TSH kit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, USA) were measured by radioimmunoassay at the beginning and the end of the experimental period.

Hemodynamic parameters

After 28 days of treatment, the animals were anesthetized with urethane (1 g/kg ip). A tracheotomy was performed using polyethylene
tubing (4mm ID, Portex). Mean arterial pressure (MAP) was measured through a cannula inserted into the right femoral artery and connected to a pressure transducer (Statham P23 ID, Gould Inst, Cleveland, OH, USA). Measurements were recorded with a polygraph (Physiograph E & M, Houston, TX, USA) during the whole experiment. Heart rate (HR) was determined from the pulsatile pressure signal by beat-to-beat conversion with a tachograph amplifier (model S77-26 tachometer, Coulbourn Instruments, Allentown, PA, USA). The Labtech Notebook program (Laboratory Technology, Wilmington, MD, USA) was used for data acquisition.

Experimental protocol

Eut, Hyper and hypo animals were subdivided into two experimental groups:

1) Control rats (C). After a 30-min stabilization period, MAP and HR were continuously recorded over a 120-min period. (n=8 each group).

2) Hemorrhaged rats (H). After a 30-min stabilization period, basal MAP and HR were measured over a 5-min period. Subsequently, the acute hemorrhage was performed. Thereafter, hemodynamic parameters were continuously recorded over a 120-min period after the bleeding (n=8 each group). The hypovolemic state in H was induced through an acute hemorrhage using a cannula inserted in the left femoral artery (Riviero, PR10). The bleeding was done by a loss of 20% of the blood volume for 2 min. The volume of blood loss was calculated individually for every animal, from the total blood volume (7% of the body mass).

Heart mitochondrial isolation

Heart mitochondria were obtained from tissue homogenates by differential centrifugation (Sorvall- Instruments-Du Pont, Model RC5S, Buckinghamshire, England) in an ice-cold medium (1/10) containing 230 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM Tris–HCl, pH 7.4 (MSTE) for 15 s with a blade homogenizer (Kendro-Sorvall-Du Pont Inst., Asheville, NC, USA) and by five strokes in a glass–Teflon homogenizer. The homogenates were centrifuged at 600g for 10 min to discard nuclei and cell debris and the supernatant containing 230 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM Tris–HCl, pH 7.20, and KCl, 5 mM KH2PO4, 2 mM malate and 5 mM glutamate (complex I substrates), pH 7.20, and bovine serum albumin (BSA) as standard. All procedure was carried out at 0–4 °C. Protein concentrations were determined with the Folin reagent, using bovine serum albumin (BSA) as standard.

Mitochondrial O2 consumption

Mitochondrial O2 uptake was measured polarographically with a Clark-type electrode (Hansatech Oxxygraph, Hansatech Instruments Ltd, Norfolk, England). State 4 respiration was determined at 30 °C in an air-saturated (220 μM O2) reaction medium consisting of 120 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 3 mM HEPES, 1 mg ml−1 BSA, 2 mM malate and 5 mM glutamate (complex I substrates), pH 7.20, and heart mitochondrial suspension (0.1–0.3 mg mitochondrial protein ml−1). State 3O2 consumption rate was established by supplementation of this medium with 0.5 mM ADP. Respirations was expressed in ng-at O/min. mg protein, and respiratory control was calculated as the ratio of state 3/state 4 respiration rates.

Complex I activity

The enzyme activity of complex I was determined spectrophotometrically (Beckman DU 7400 spectrophotometers; 550 nm, ε=19mM−1cm−1) as NADH-cytochrome c reductase at 30 °C with mitochondrial membranes suspended in 100 mM KH2PO4/ K2HPO4, pH 7.4. Mitochondrial membranes were added with 0.2mM NADH, 25μM cytochrome c3+, and 0.5 mM KCN. Enzymatic activities were expressed as nmol reduced cytochrome c/min. mg protein.

Western blot analysis

The proteins of mitochondrial membranes (0.10 mg protein/lane) were separated by electrophoresis in 7.5% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane (Bio-Rad, Munich, Germany) and then incubated with rabbit polyclonal anti-neuronal NOS (BD Transduction Laboratories, USA) and anti-VDAC-1/2/3 (FL-283; sc-98708, Santa Cruz Biotechnology, CA) antibodies [1:500 dilution] and a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:5,000 dilution). Samples were revealed by chemiluminescence using the enhanced chemiluminescence reagent (Amersham Pharmacia Biotechnology, Uppsala, Sweden) for 4 min. Quantification of the bands was performed by digital image analysis using a Hewlett-Packard scanner and TotalLab analyzer software (Biodynamics, Seattle, WA). Data were expressed as relative to VDAC-1/2/3 expression (loading control). All experiments were performed in triplicate.

Statistical analysis

Data in tables and figures are mean values ±SEM. Data were evaluated with univariate and multivariate approaches for a completely randomized design, with a structure of two factors (hemorrhage and thyroid hormones). For each variable, ANOVA or MANOVA analysis was performed when appropriate. The Levene’s and Shapiro-Wilk’s tests were used to evaluate homogeneity of variances and normality of data, respectively. When normality and homogeneity of variances assumptions were satisfied, the Bonferroni multiple comparison test was run. In the case of non-homogenous variances, a multiple comparison test, such as Tamhane, was run. To detect association among variables, a correlation analysis was performed and the Pearson coefficient was calculated. All statistical procedures were performed using the SPSS statistical software package version 22.0 statistical significance was set at P<0.05.

Results

Treatment efficacy

TSH plasmatic levels were higher and lower in hypo and Hyper rats respectively. T1 and T2 levels decreased in hypo rats, while T4 increased in Hyper animals. Body weights and basal MAP values were similar in the three groups of animals. However, basal HR values were lower and higher in hypo and Hyper rats compared with Eut animals, respectively. Bleeding induced a decreased of MAP values in all experimental groups. However, animals with thyroid disorder exhibited a lower MAP values at 120 minutes of hemorrhage than Eut (Table 1).

Mitochondrial respiratory function

The malate-glutamate-supported state 3 respiration was decreased in hypo rats and increased in hyper rats. Hemorrhage did not change state 3 respiration in all groups of animals. No differences were observed in malate-glutamate-supported state 3 between experimental groups. Withdrawal did not modify this state (Table 2). Respiratory control and ADP-to-O ratios were high indicating that the mitochondria were well coupled and able to effectively carry out oxidative phosphorylation. After bleeding, it was observed a tendency of ADP-to-O ratio to decrease in hypo animals (Table 2).
**Table 1** Biological variables

<table>
<thead>
<tr>
<th>Animals</th>
<th>Eut</th>
<th>Hypo</th>
<th>Hyper</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH (ng/ml)</td>
<td>14.75±0.83</td>
<td>35.57±4.35*</td>
<td>5.57±0.03*</td>
</tr>
<tr>
<td>T3 (ng/dl)</td>
<td>1.13±0.123</td>
<td>0.75±0.036*</td>
<td>1.03±0.036</td>
</tr>
<tr>
<td>T4 (ug/ml)</td>
<td>2.475±0.031</td>
<td>1.03±0.036*</td>
<td>3.77±0.270*</td>
</tr>
<tr>
<td>BW (g)</td>
<td>337±12</td>
<td>338±12</td>
<td>298±12</td>
</tr>
<tr>
<td>Basal HR (bpm)</td>
<td>352±15</td>
<td>214±13*</td>
<td>424±15*</td>
</tr>
<tr>
<td>At 120 min HR (bpm)</td>
<td>364±12</td>
<td>222±10*</td>
<td>480±10*</td>
</tr>
<tr>
<td>Basal MAP(mmHg)</td>
<td>80±4</td>
<td>70±4</td>
<td>76±2</td>
</tr>
<tr>
<td>At 120 min MAP (mmHg)</td>
<td>58±3</td>
<td>45±2*</td>
<td>41±2*</td>
</tr>
<tr>
<td>LVIDd (mm)</td>
<td>5.40±0.18</td>
<td>5.99±0.19*</td>
<td>4.7±0.10*</td>
</tr>
<tr>
<td>LVIDs (mm)</td>
<td>2.80±0.06</td>
<td>3.01±0.10*</td>
<td>2.21±0.07*</td>
</tr>
<tr>
<td>EF (%)</td>
<td>86±3</td>
<td>83±1*</td>
<td>88±3</td>
</tr>
<tr>
<td>FS (%)</td>
<td>56±2</td>
<td>46±2*</td>
<td>51±2</td>
</tr>
</tbody>
</table>

Eut, Euthyroid rats; hypo, Hypothyroid rats; Hyper, Hyperthyroid rats; TSH, Thyroid-stimulating hormone; T3, Triiodothyronine; T4, Total thyroxine; BW, Body weight; HR, Heart rate; MAP, Mean arterial pressure; LVIDd, LV internal diameter in diastole; LVIDs, LV internal diameter in systole; EF, Ejection fraction; FS, Fractional shortening. Data are mean ± SEM; n=15; *P<0.05 vs Eut rats.

**Table 2** Heart mitochondria function in thyroid disorder and hypovolemia

<table>
<thead>
<tr>
<th>O₂ Uptake, ng-atoms O₂ min⁻¹mg protein⁻¹</th>
<th>State 4</th>
<th>State 3</th>
<th>Respiratory control ratio</th>
<th>ADP-to-O ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malate-glutamate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eut</td>
<td>42 ± 3</td>
<td>216 ± 13</td>
<td>5.2</td>
<td>2.50 ± 0.08</td>
</tr>
<tr>
<td>EutH</td>
<td>45 ± 3</td>
<td>228 ± 10</td>
<td>5.1</td>
<td>2.49 ± 0.17</td>
</tr>
<tr>
<td>hypo</td>
<td>35 ± 2</td>
<td>177 ± 7*</td>
<td>5.1</td>
<td>2.54 ± 0.19</td>
</tr>
<tr>
<td>hypoH</td>
<td>40 ± 2</td>
<td>174 ± 4</td>
<td>4.3</td>
<td>2.13 ± 0.06</td>
</tr>
<tr>
<td>Hyper</td>
<td>40 ± 2</td>
<td>260 ± 14*</td>
<td>6.5</td>
<td>2.54 ± 0.09</td>
</tr>
<tr>
<td>HyperH</td>
<td>42 ± 2</td>
<td>257 ± 13</td>
<td>6.1</td>
<td>2.57 ± 0.23</td>
</tr>
</tbody>
</table>

Eut, Euthyroid rats; hypo, Hypothyroid rats; Hyper, Hyperthyroid rats; H, Hemorrhaged. Data are mean ± SEM; n=15; *P<0.05 vs Eut rats.

**Complex I activity**

Enzyme activity was only decreased in hypo rats. This activity was increased after bleeding in hypo animals. The complex I activity did not change in Hyper animals and the bleeding did not change this parameter (Table 3).

---

**Citation:** Ogonowski N, Valdez LB, Zaobornyj T, et al. Thyroid hormones and heart mitochondrial nitric oxide under hypovolemia. *Endocrinol Metab Int J.* 2018;6(5):343–347. DOI: 10.15406/emij.2018.06.00201
Thyroid hormones and heart mitochondrial nitric oxide under hypovolemia

Table 3 Complex I activity in heart mitochondria in thyroid disorder and hypovolemia

<table>
<thead>
<tr>
<th>Animals</th>
<th>Complex I (nmol/min .mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eut</td>
<td>204 ± 44</td>
</tr>
<tr>
<td>Eut H</td>
<td>182 ± 18</td>
</tr>
<tr>
<td>hypo H</td>
<td>117 ± 16*</td>
</tr>
<tr>
<td>hypo</td>
<td>147 ± 17†</td>
</tr>
<tr>
<td>Hyper</td>
<td>179 ± 14</td>
</tr>
<tr>
<td>Hyper H</td>
<td>179 ± 10</td>
</tr>
</tbody>
</table>

Eut, Euthyroid rats; hypo, Hypothyroid rats; Hyper, Hyperthyroid rats; H, Hemorrhaged. Data are mean ± SEM; n=15; *P<0.05 vs Eut rats; † P<0.05 vs rats without hemorrhage.

Nitric oxide synthase in heart mitochondria

Figure 1 showed that hypothyroidism decreased nNOS protein levels compared with Eut group. This protein levels did not change in Hyper animals. Withdrawal decreased nNOS protein levels in hypo and Eut rats, while did not change in Hyper animals.

Discussion

This study showed, for the first time, interesting findings that heart mitochondrial function is altered during thyroid disorder and acute hypovolemia. Heart mitochondrial NO, modulating oxygen uptake, may be involved in the adaptive response to assure the cardiomyocytes survives in this experimental condition.

Several authors show that thyroid hormones have a special role regulating heart function. In this context, cardiovascular system regulation would be crucial in these pathological situations of hypovolemia. In this study, TSH measurements showed that both treatments were effective to establish thyroid disorder. Basal MAP values were similar in all experimental groups of rats. These findings were like those obtained by us previously and were discussed previously. The hemodynamics changes let us to evaluate the mitochondrial function in the experimental groups. The determination of this function was achieved by measuring O2 consumption in presence of saturating concentrations of the respective substrates. Thyroid state only affects state 3 of respiration using malate-glutamate as a substrate, while no changes were observed in oxygen consumption during state 4. Additionally, it is important to note that oxygen uptakes did not change in hypovolemic-induced acute cellular stress. Complex I activity decreased only in hypothyroidism. This finding agreed with those found by several authors. This effect could be probably controlled by a variety of mechanisms such as reduced content and activity of some components of the electron transport chain, alterations of mitochondrial membranes permeability as well as changes in lipid composition. Additionally, Mukherjee et al., showed that complex I activity was inhibited in hypothyroid submitochondrial particles, whereas T supplementation upregulated electron transport chain complexes. Although it is well known that T upregulates all the respiratory chain complexes of inner mitochondrial membrane accounting for enhanced oxygen consumption as it was shown by our results. On the other hand, we observed that hemorrhage decreased this complex I activity only in hypo group. In accordance with our results, we suggest that complex I seems to be a vulnerable target in hypothyroid condition. While several factors may be responsible of this effect, we focused on mitochondrial NO production. The results showed that mtNOS protein levels only decreased in hypo animals compared with Eut rats. This result would be disagreed with several authors who showed in other tissues like liver and skeletal muscle, an increased mtNOS expression in hypothyroidism. That is, hypothyroidism is associated with a lower activity of complex I and lower mtNOS protein level in mitochondrial heart compared with Eut animals. Parihar et al. showed a similar result suggesting that rat liver and brain mtNOS are functionally associated with mitochondrial respiration chain complex I. Additionally, our study also showed that this interaction would depend on thyroid hormone levels. Interestingly, mitochondrial dysfunction is often associated with critical care diseases such as sepsis, trauma and acute hemorrhagic. The results show that in our experimental conditions the hypovolemia induced by acute bleeding did not modify the oxygen consumption in any of the three groups of animals. On the other hand, we also show that the maintenance of normal respiration after bleeding was associated with a decrease in the levels of mtNOS only in Eut and hypothyroid animals. These findings suggest that mtNOS would be related to energy demand and it reacts differently depending thyroid state and volemia.

Conclusion

The data presented in this study provide the following novel information: heart mitochondrial function is altered during thyroid disorder and acute hypovolemia. The decrease of thyroid hormone level would probably be a hormonal environment that promotes...
changes in mitochondrial NO bioavailability modulating oxygen consumption and cell respiration even against acute hypovolemic stress. Alterations of complex I activity could mediate these effects.

Acknowledgements

None.

Conflict of interest

The author declares there is no conflict of interest.

References